Center on Health Equity & Access

Clinical

Health Care Cost

Health Care Delivery

Insurance

Policy

Technology

Value-Based Care

News

All News

Press Releases

Product Approvals and Launches

Video

All Video Types

AJMC TV

Insights

OnLocation

Payer Perspectives

Peer Exchange

Post Conference Perspectives

Stakeholder Summit

Podcasts

Conferences

Conference Coverage

Conference Listing

Journals

All Journals

The American Journal of Managed Care

Population Health, Equity & Outcomes

Evidence-Based Oncology

About Supplements and Featured Publications

Supplements and Featured Publications Issues

Submit a Manuscript

Events

Institute for Value-Based Medicine

Patient-Centered Oncology Care

Resources

Interactive Tools

Clinical Spotlight

Microsites

About AJMC

AJMC Staff

Anniversary

Seema Sonnad Award

Strategic Alliance Partners

Subscribe

Kimberly Rath, PharmD, is a freelance health writer who previously worked as a clinical pharmacist with Elevance Health for a decade. She has also worked for Amerigroup and Sentara Group.

Articles

A new study aimed at exploring the relationship between obesity and multiple sclerosis severity using genetic data finds that higher BMI and other obesity measures were associated with increased disability progression in patients with MS.

Study Finds Obesity May Worsen Multiple Sclerosis: Genetic Analysis Points to Causal Link

For patients with chronic lymphocytic leukemia (CLL) treated previously with venetoclax and Bruton’s tyrosine kinase inhibitors, many more trials are needed to pinpoint the best next steps 

Treating Double-Exposed Patients With CLL: A Continued Unmet Need

Julia is an associate editor for The American Journal of Managed Care® (AJMC®) and joined AJMC® in 2022. She produces written and video content covering multiple disease states, and assists in the screening process for manuscripts submitted to AJMC®.

She has a BA in English language and literature from Rutgers University. You can connect with Julia on 

Women living with HIV can reduce their risk of cervical cancer using a human papillomavirus (HPV) vaccine that is both cost-effective and effective in preventing the virus.

HPV Vaccination Cost-Effective at Preventing Cervical Cancer in Patients With HIV

Cameron Santoro is an associate editor for 

), AJMC.com, and The Center for Biosimilars

Over half of the US adult population may benefit from semaglutide, a drug primarily used for weight loss and diabetes, although concerns about access and cost persist, especially considering its potential for wider health applications.

Semaglutide Eligibility Expands to Over Half of US Adults

The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia platforms.

About

Contact

Editorial Boards

Advertise

Do Not Sell My Information

Terms & Conditions

Privacy Policy

AJMC - Managed Care News, Research, and Expert Insights

Facebook

Twitter

LinkedIn

Instagram

Specialty Area

Biosimilars

Cardiorenalmetabolic

Dermatology

Hematology

Hepatology

Immunology

Infectious Disease

Mental Health

Neurology

Obesity

Oncology

Ophthalmology

Pulmonology

Rare Disease

Respiratory

Rheumatology

Women's Health

Spotlight

Free In-Person Regional Events Focused on Oncology and Population Health

Topics

Digital Health

Formulary

Gene Therapy

Guidelines

Health Care Administration

Population Health

All Coverage

Event Coverage

Interviews

AJMC Journals

Author Forms

Authors

Nominate a Rising Leader

View

ASCO 2024: Updates in Multiple Myeloma 

Video Series

Long-Term Follow-Up Data from MajesTEC-1 at ASCO 2024

Video content above is prompted by the following:

Discuss the data you presented at the 2024 ASCO Annual Meeting on long-term follow-up from the phase 1/2 MajesTEC-1 trial of teclistamab in patients with relapsed/refractory multiple myeloma (RRMM).

How was this study designed/what methodology was used?

Videos

Alfred L. Garfall, MD, shares insights to recent data surrounding the multiple myeloma treatment landscape as presented at ASCO 2024 in Chicago, Illinois.

Alfred L. Garfall, MD, opens a discussion underscoring the unmet needs in multiple myeloma.

Unmet Needs in Multiple Myeloma Ahead of ASCO 2024

Dr Garfall, MD, provides insights following results derived from the MajesTEC-1 study.

Dr Garfall, MD, provides further insights around the MajesTEC-1 study.

MajesTEC-1 and the Value of Long-Term Follow-Up Data from ASCO 2024

Alfred L. Garfall, MD, discusses long-term follow-up data from the MajesTEC-1 study presented at ASCO 2024.

Use of Prophylactic Tocilizumab with Teclistamab: Takeaways from ASCO 2024

Alfred L. Garfall, MD, discusses follow-up data from the DREAMM-8 study presented at ASCO 2024.

ASCO 2024: DREAMM-8 Study of Belantamab Mafodotin, Pomalidomide, and Dexamethasone

Alfred L. Garfall, MD, discusses his hopes for the future treatment landscape of multiple myeloma. 

Future Directions in the Management of Multiple Myeloma 

Long-Term Follow-Up Data from MajesTEC-1 at ASCO 2024

EP: 1.Unmet Needs in Multiple Myeloma Ahead of ASCO 2024

EP: 2.Long-Term Follow-Up Data from MajesTEC-1 at ASCO 2024

EP: 3.MajesTEC-1 and the Value of Long-Term Follow-Up Data from ASCO 2024

EP: 4.Use of Prophylactic Tocilizumab with Teclistamab: Takeaways from ASCO 2024

EP: 5.ASCO 2024: DREAMM-8 Study of Belantamab Mafodotin, Pomalidomide, and Dexamethasone

EP: 6.Future Directions in the Management of Multiple Myeloma